Journal ArticleOPEN ACCESS

Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway

  • Ma C
  • Liu M
  • Feng W
  • et al.
Clinical and Translational Medicine (2023) 13(11)
DOI: 10.1002/ctm2.1475
N/ACitations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Graphical Abstract • SETD2 deficiency promotes the progression of SMAD4-deficient CRC. • SETD2 deletion exacerbates SMAD4-deficient CRC via RAS/ERK signalling pathway. • SETD2 inhibits the RAS/ERK signalling pathway by promoting DUSP7 transcription. Clin. Transl. Med. 2023;13:e1475. wileyonlinelibrary.com/journal/ctm2 https://doi.

Cite

CITATION STYLE

APA

Ma, C., Liu, M., Feng, W., Rao, H., Zhang, W., Liu, C., … Li, L. (2023). Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway. Clinical and Translational Medicine, 13(11). https://doi.org/10.1002/ctm2.1475

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free